The company is developing living mammalian cell arrays for drug-discovery and -development applications. The four new grants, which the NIH said are effective as of Dec. 26, include:
- $920,940 for the detection of bioterrorism agents with [the company's phenotype microarray] technology;
- $650,000 to develop the phenotype array for drug toxicity screening;
- $276,981 to develop the array for analysis of "fastidious pathogens;" and
- $123,238 to phenotype all the genes of S. cerevisae.